



Dkt. 41426-A-PCT-US/JPW/CY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ron S. Israeli et al.

Serial No.: 08/403,803 Group Art Unit: 1647

Filed: March 17, 1995 Examiner: S. Gucker

For: PROSTATE-SPECIFIC MEMBRANE ANTIGEN

1185 Avenue of the Americas
New York, New York 10036
November 16, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Mail Stop AF

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following documents which are listed on the attached Form PTO-1449 (**EXHIBIT A**). Copies of the documents listed below as items 1 and 2 are attached hereto as **EXHIBITS 1** and **2**:

1. Communication Pursuant To Article 115(2) EPC issued August 30, 2004 in connection with related European Patent Application No. 94 90 0538.3 (**EXHIBIT 1**); and
2. Holmes, Eric H., "PSMA specific antibodies and their diagnostic and therapeutic use," Exp. Opin. Invest. Drugs, 10(3):511-519 (2001) (**EXHIBIT 2**).

11/18/2004 GWORDOF1 00000060 08403803

01 FC:1806

180.00 0P

Applicants: Ron S. Israeli, et al.

Serial No.: 08/403,803

Filed: March 17, 1995

Page 2

Document 2 was cited in Document 1, an August 30, 2004 Communication Pursuant To Article 115(2) EPC issued in connection with related European Patent Application No. 94 90 0538.3. Copies of Documents 1 and 2 are attached hereto as **EXHIBITS 1 and 2**, respectfully.

Pursuant to 37 C.F.R. §1.97(d)(2), the required fee for filing this Supplemental Information Disclosure Statement is ONE-HUNDRED AND EIGHTY DOLLARS (\$180.00), and a check for this amount is enclosed.

Furthermore, under 37 C.F.R. §1.97(e)(1), applicants certify that each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Applicants: Ron S. Israeli, et al.
Serial No.: 08/403,803
Filed: March 17, 1995
Page 3

No fee, other than the enclosed \$180.00 fee for filing a Supplemental Information Disclosure Statement, is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

John P. White 11/16/04
John P. White Date
Reg. No. 28,678

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Application Number	08/403,803
 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Filing Date	March 17, 1995		
		First Named Inventor	Ron S. Israeli		
		Art Unit	1647		
		Examiner Name	S. Gucker		
		Attorney Docket No.	1769/41426-A-PCT-US/JPW/CY		
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		Communication Pursuant To Article 115(2) EPC issued August 30, 2004 in connection with related European Patent Application No. 94 90 0538.3 (EXHIBIT 1); and			
		HOLMES, ERIC H., "PSMA specific antibodies and their diagnostic and therapeutic use," <u>Exp. Opin. Invest. Drugs</u> , 10(3):511-519 (2001) (EXHIBIT 2)			
EXAMINER SIGNATURE		DATE CONSIDERED			

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² Applicant is to place a checkmark here if English language Translation is attached.

Applicants: Ron S. Israeli et al.
Serial No.: 08/403,803
Filed: March 17, 1995
Exhibit A